ClinicalTrials.gg
CompletedNCT05033639Updated Jun 20, 2024

Efficacy Of Oral Melatonin To Prevent Necrotizing Enterocolitis

A Phase 1/2 interventional study of Melatonin 6 MG and Breast Milk in Necrotizing Enterocolitis, sponsored by Ilocos Training and Regional Medical Center. Completed at 1 site in Philippines. Open to participants aged 28 Weeks to 36 Weeks. Per ClinicalTrials.gov, last updated 2024-06-20.

Sponsored by Ilocos Training and Regional Medical Center · Phase 1/2, Interventional, and Prevention

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Mar 2021, registered Aug 2021).
Phase
Phase 1/2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
28 Weeks to 36 Weeks
Sex
All
01

Study summary

Prematurity is still one of the primary causes of death in children under 5. 1-2. According to the WHO, 60% of all preterm births occur in Asia, with the Philippines accounting for around 348,900 every year. 3. Necrotizing enterocolitis is one of the fatal complications (NEC) 3, 4. Preterm newborns weighing 1500 grams or less are considered high risk. 5-6.

Melatonin is one chemical that may help prevent NEC. Melatonin is an endogenous indolamine derived from serotonin. It is a ubiquitous molecule that is crucial to the body's physiologic function. Melatonin, also known as N-acetyl-5-methoxytryptamine, is an immunomodulator, antioxidant, anti-inflammatory, and free radical scavenger7-10.

It is a naturally occurring chemical that is simply replenished. With this in mind, the researcher wants to see if providing high dose melatonin to premature babies can prevent NEC.

Read the detailed description

Prematurity remains as one of the leading causes of mortality among children less than 5 years old1-2. The World Health Organization that 60 percent of all preterm births around the world occurs in Asian countries and roughly 348,900 births occur each year in the Philippines3. One complication that contribute to the high mortality is necrotizing enterocolitis (NEC)1, 3-4. High risk population include preterm infants weighing 1500 grams and lower with inverse correlation to the patient's weight5-6.

One compound that could be used to prevent NEC is melatonin. Melatonin is an endogenously produced indolamine principally synthesized in the pineal gland from serotonin. It is described as a ubiquitous molecule which plays a vital role in the physiologic function of the body. Melatonin, also known as N-acetyl-5-methoxytryptamine which has a a) immunomodulator; b) free radical scavenger; c) prevention of oxidative stress and d) anti-inflammatory7-10.

It is a naturally occurring substance and it would just be supplemented to increase its levels. With all this in mind, the researcher would like to determine if giving high dose melatonin among preterm neonates could prevent NEC among high risk population.

02

Conditions studied

  • Necrotizing Enterocolitis
03

In context

Enterocolitis, Necrotizing

228 studies on the registry are indexed under Enterocolitis, Necrotizing; 44 are open to participants now.

This study's enrollment of 100 is close to the median of 103 across 127 interventional studies indexed under Enterocolitis, Necrotizing.

Browse Enterocolitis, Necrotizing studies →

Lead sponsor

Ilocos Training and Regional Medical Center is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
28 Weeks to 36 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Newborn with a pediatric age of less than 37 weeks categorized very preterm (28 to 32 weeks) and late preterm (32 to 36weeks) by the World Health Organization weighing not more than 1500.

      1. Preterm infants admitted at the Neonatal Intensive care unit of Ilocos Training Regional and Medical Center not more than 24 hours of age.
      1. Preterm infants with orogastric tube in place. 4. Preterm infants with no other condition other than prematurity and respiratory distress syndrome.
      1. Preterm infant with an Apgar score of more than 6 in the first minute of life.

Exclusion criteria

Exclusion Criteria:

  1. Preterm infants more than 1 day of life.
  2. Preterm infants diagnosed with NEC
  3. Preterm infants who is born to a mother of who considered as a minor (\<18 years old) and is not married to the father of the unborn child.
  4. Preterm infants that could not be fed through oral gastric tube due to a secondary problem.
  5. Preterm infants with other comorbidities such as asphyxia, congenital anomalies, and other inherited disorders.
  6. Meconium Stained Preterm infants

    -

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Treatment Group

    Other than the Standard Management of preterm infant, treatment group A infants will receive 6 mg tablet dissolved in 5 ml breastmilk via oral gastric tube administered once a day at 10 pm.

    Drug: Melatonin 6 MG

  • Placebo comparator
    Control Group

    Human breast milk 5ml would be used as the placebo in this study. It would be indistinguishable from the treatment group as this will also be the diluent used.

    Other: Breast Milk

Interventions

  • Melatonin is an endogenously produced indolamine principally synthesized in the pineal gland from serotonin. It is described as a ubiquitous molecule which plays a vital role in the physiologic function of the body. Melatonin, also known as N-acetyl-5-methoxytryptamine which has a a) immunomodulator; b) free radical scavenger; c) prevention of oxidative stress and d) anti-inflammatory7-10.

  • OtherBreast Milk

    Naturally occurring milk from the mother of the infant.

06

What researchers measure

Primary outcomes

  1. Number Of Preterm Infants Who Developed Necrotizing Enterocolits After Melatonin 6mg Tablet Prophylaxis

    effectiveness of melatonin in preventing NEC among preterm infants with a birthweight of \</ = 1500 kg at Ilocos Training and Regional Medical Center.

    Time frame: 5 MONTHS

Secondary outcomes

  1. Incidence of Prematurity at Training and Regional Medical Center

    Clinical Profiles Of Preterm Infants Born In Ilocos Training and Regional Medical Center

    Time frame: 5 MONTHS

  2. Number of Patients Who Developed Abnormal Gas Pattern with Dilated Bowel Loops after Melatonin 6mg Tablet Prophylaxis

    Absence of Clinical And Radiologic Findings Diagnostic of Necrotizing Enterocolitis.

    Time frame: 5 MONTHS

  3. Number of Patients Who Developed Pneumatosis intestinalis after Melatonin 6mg Tablet Prophylaxis

    Absence of Clinical And Radiologic Findings Diagnostic of Necrotizing Enterocolitis.

    Time frame: 5 Months

  4. Number of Patients Who Developed Sentinel Loops after Melatonin 6mg Tablet Prophylaxis

    Absence of Clinical And Radiologic Findings Diagnostic of Necrotizing Enterocolitis.

    Time frame: 5 Months

  5. Number of Patients Who Developed Portal Venous Gas after Melatonin 6mg Tablet Prophylaxis

    Absence of Clinical And Radiologic Findings Diagnostic of Necrotizing Enterocolitis.

    Time frame: 5 Months

  6. Number Of Hospital Days Among Preterm Infants Admitted at Ilocos Training and Regional Medical Center

    Efficacy of Melatonin Oral Prophylaxis

    Time frame: 5 Months

  7. Number Of Days Before Oral FeedingAmong Preterm Infants Admitted at Ilocos Training and Regional Medical Center

    Efficacy of Melatonin Oral Prophylaxis

    Time frame: 5 motnhs

07

Study locations

1 site
  • Ilocos Training and Regional Medical Center
    San Fernando, LA Union 2500, Philippines
08

References and documents

Individual participant data

Plan to share: No — due to the data privacy act of the philippines, individual data cannot be shared however the completed data will be shared

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05033639
Lead sponsor
Ilocos Training and Regional Medical Center
Collaborators
Vayu Global Foundation
Responsible party
Navid Roodaki (Pediatric Chief Resident, Ilocos Training and Regional Medical Center) — Principal investigator
First posted
Sep 5, 2021
Start date
Mar 1, 2021
Primary completion
Dec 31, 2021
Completion
Dec 31, 2021
Last update
Jun 20, 2024

Study contacts

Daisy Evangeline C Garcia, MD
study director · Ilocos Training and Regional Medical Center
Navid P Roodaki, MD
principal investigator · ITRMC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Melatonin

Start the discussion